Lifevantage Corp
Business
LifeVantage Corporation is a direct-sales company focused on nutrigenomics, developing and selling scientifically validated dietary supplements, skin and hair care products, weight management items, and nootropic energy drinks through independent consultants. Core product lines include Protandim® (antioxidant supplements), LifeVantage® (including the MindBody GLP-1 System), TrueScience® (skin and hair care), PhysIQ™ (weight management), Petandim® (pet supplements), and AXIO® (nootropic energy drinks). The company operates in the United States, Japan, Australia, Mexico, Canada, and Europe, distributing exclusively through its independent consultant network and direct-to-consumer channels.
Summary from 10-K filed 2025-09-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue, net | 229 | 200 | 213 | 206 | 220 | |
| Cost of sales | 45 | 41 | 43 | 38 | 38 | |
| Gross profit | 184 | 159 | 170 | 168 | 182 | |
| Commissions and incentives | 102 | 86 | 95 | 97 | 104 | |
| Selling, general and administrative | 69 | 68 | 71 | 63 | 61 | |
| Total operating expenses | 171 | 154 | 166 | 161 | 164 | |
| Operating income | 12 | 4 | 4 | 8 | 18 | |
| Interest income, net | 431,000 | 430,000 | — | — | — | |
| Other expense, net | −387,000 | −412,000 | −458,000 | −669,000 | −366,000 | |
| Total other income, net | 44,000 | 18,000 | −260,000 | −3 | −383,000 | |
| Income before income taxes | 12 | 4 | 4 | 5 | 17 | |
| Income tax expense | −2 | −1 | −1 | −2 | −4 | |
| Net income | 10 | 3 | 3 | 3 | 13 | |
| Basic (dollars per share) | 0.8 | 0.24 | 0.2 | 0.24 | 0.92 | |
| Diluted (dollars per share) | 0.75 | 0.23 | 0.2 | 0.24 | 0.9 | |
| Basic (in shares) | 12 | 12 | 13 | 13 | 14 | |
| Diluted (in shares) | 13 | 13 | 13 | 13 | 14 | |
| Foreign currency translation adjustment | 741,000 | −555,000 | −238,000 | −1 | −40,000 | |
| Other comprehensive income (loss), net of tax: | 741,000 | −555,000 | −238,000 | −1 | −40,000 | |
| Comprehensive income | 11 | 2 | 2 | 2 | 13 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 17 | 22 | 20 | 23 | |
| Accounts receivable | 3 | 3 | 2 | 3 | 3 | |
| Income tax receivable | 635,000 | 313,000 | 241,000 | 2 | 1 | |
| Inventory | 21 | 15 | 16 | 16 | 16 | |
| Prepaid expenses and other | 6 | 2 | 5 | 5 | 5 | |
| Total current assets | 51 | 38 | 44 | 47 | 48 | |
| Property and equipment, net | 6 | 8 | 9 | 10 | 11 | |
| Right-of-use assets | 8 | 10 | 9 | 11 | 14 | |
| Intangible assets, net | 245,000 | 323,000 | 455,000 | 587,000 | 719,000 | |
| Deferred income tax asset | 6 | 4 | 3 | 1 | 1 | |
| Other long-term assets | 601,000 | 680,000 | 569,000 | 1 | 2 | |
| TOTAL ASSETS | 72 | 60 | 66 | 71 | 79 | |
| Accounts payable | 5 | 6 | 4 | 7 | 7 | |
| Commissions payable | 7 | 7 | 7 | 7 | 8 | |
| Income tax payable | 0 | 202,000 | 0 | 453,000 | 830,000 | |
| Lease liabilities | 2 | 2 | 2 | 3 | 2 | |
| Other accrued expenses | 14 | 8 | 8 | 8 | 7 | |
| Total current liabilities | 27 | 22 | 20 | 26 | 25 | |
| Long-term lease liabilities | 10 | 12 | 12 | 13 | 16 | |
| Other long-term liabilities | 289,000 | 198,000 | 299,000 | 308,000 | 694,000 | |
| Total liabilities | 37 | 34 | 31 | 39 | 42 | |
| Commitments and contingencies Note 14 | — | — | — | — | — | |
| Preferred stock par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock par value $0.0001 per share, 40,000 shares authorized and 12,429 and 12,510 issued and outstanding as of June 30, 2025 and 2024, respectively | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
| Additional paid-in capital | 140 | 137 | 134 | 131 | 129 | |
| Accumulated deficit | −104 | −109 | −98 | −98 | −92 | |
| Accumulated other comprehensive loss | −1 | −2 | −1 | −1 | 104,000 | |
| Total stockholders equity | 35 | 26 | 35 | 32 | 37 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 72 | 60 | 66 | 71 | 79 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3 | 4 | 4 | 3 | 3 | |
| Stock-based compensation | 6 | 3 | 3 | 2 | 2 | |
| Non-cash operating lease expense | 1 | 1 | 2 | 2 | 2 | |
| (Gain) loss on disposal of fixed assets | −4,000 | 2,000 | 33,000 | 0 | −7,000 | |
| Amortization of deferred financing fees | 32,000 | 7,000 | 0 | 0 | 0 | |
| Deferred income tax | −2 | −1 | −2 | −81,000 | 955,000 | |
| Accounts receivable | −242,000 | −1 | 2 | −614,000 | −265,000 | |
| Income tax receivable | −322,000 | −71,000 | 2 | −713,000 | −1 | |
| Inventory | −5 | 662,000 | 61,000 | −1 | −2 | |
| Prepaid expenses and other | −4 | 2 | 1 | −551,000 | 486,000 | |
| Other long-term assets | 72,000 | −55,000 | −157,000 | 139,000 | 59,000 | |
| Accounts payable | −1 | 2 | −4 | 824,000 | 3 | |
| Income tax payable | −201,000 | 202,000 | −453,000 | −377,000 | 46,000 | |
| Other accrued expenses | 6 | −176,000 | −770,000 | 357,000 | −4 | |
| Lease liabilities | −2 | −2 | −2 | −2 | −2 | |
| Other liabilities | 63,000 | 247,000 | 257,000 | −335,000 | −293,000 | |
| Net Cash Provided by Operating Activities | 12 | 12 | 7 | 8 | 16 | |
| Purchase of equipment | −1 | −2 | −3 | −2 | −4 | |
| Proceeds from sale of fixed assets | 4,000 | 0 | 8,000 | 0 | 7,000 | |
| Net Cash Used in Investing Activities | −1 | −2 | −3 | −2 | −4 | |
| Payment of deferred financing fees | 0 | −97,000 | 0 | — | — | |
| Repurchase of company stock | −3 | −6 | −800,000 | −9 | −12 | |
| Payment of cash dividends | −2 | −7 | −2 | −378,000 | 0 | |
| Shares purchased as payment of tax withholding and other | −3 | −1 | −201,000 | −246,000 | −1 | |
| Proceeds from common stock issued under employee stock purchase plan | 280,000 | 271,000 | 252,000 | 372,000 | 517,000 | |
| Net Cash Used in Financing Activities | −8 | −14 | −2 | −9 | −11 | |
| Foreign Currency Effect on Cash | 402,000 | −254,000 | 3,000 | −461,000 | −50,000 | |
| Increase (Decrease) in Cash and Cash Equivalents | 3 | −5 | 1 | −3 | 1 | |
| Cash paid for interest | 2,000 | 21,000 | 5,000 | 10,000 | 17,000 | |
| Cash paid for income taxes | 5 | 2 | 2 | 3 | 4 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lifevantage Corp's CIK number?
Lifevantage Corp's SEC CIK number is 0000849146 (849146). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lifevantage Corp's SEC filings?
All of Lifevantage Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Lifevantage Corp last report earnings?
Lifevantage Corp (LFVN) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-208934). This is Lifevantage Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is Lifevantage Corp's most recent earnings 8-K?
Lifevantage Corp's latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-208934. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Lifevantage Corp's latest earnings 8-K →
Look up any company's CIK number →